"As a big multinational pharmaceutical company, GSK China in recent years rampantly bribed some government officials, a number of pharmaceutical industry groups and funds, hospitals and doctors," the ministry of public security said in a statement.
The firm did so in order to sell products or raise prices, it said, adding that benefits were provided "via travel agencies and other channels in the form of direct bribery or sponsorship".
It also committed tax-related crimes, the statement said, following police investigations in the financial hub Shanghai and the central cities of Changsha and Zhengzhou.
Some senior managers have confessed their wrongdoings in preliminary interrogation, the statement said, without specifying the suspects' nationalities.
The inquiry was continuing.
It is common practice in China for pharmaceutical firms to offer doctors and hospitals bribes to have their products used, industry insiders say.
GSK is one of the largest multinational pharmaceutical companies in China with total investment of more than USD 500 million, according to its website.
Officials at GSK said they could not immediately comment when contacted by AFP today.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
